Cordis Endovascular’s CYPHER SELECT™ Sirolimus- eluting stent has recently received CE (Communite European) Mark in Europe for use in the treatment of severe claudication and critical limb ischemia (CLI) of infrapopliteal lesions -- the most severe form of arterial disease in the leg.
Cordis Endovascular’s CYPHER SELECT™ Sirolimus-eluting stent is the first drug- eluting stent to obtain CE approval for severe claudication and critical limb ischemia (CLI) that is associated with infrapopliteal lesions.
Characterized by severe obstruction of the arteries, severe claudication and CLI significantly decreases blood flow to the areas of the leg below the knee: a condition marked by severe pain and skin ulcers or sores that could possibly require amputation.
The abovementioned European regulatory approval enables Cordis Endovascular (a division of Cordis Corporation,12789533) to offer the CYPHER SELECT™ Sirolimus-eluting stent for the treatment of infrapopliteal severe claudication and CLI patients in all countries within the European Union.
Read more details from the press release.
Comment Preview